格隆汇12月15日丨荣昌生物(688331.SH)公布，本次回购的股份拟用于员工持股计划或股权激励，回购 股份金额不低于人民币2,000万元（含），不超过人民币4,000万元（含）。回购股份价格不超过95元/股 （含）。 ...

格隆汇12月15日丨荣昌生物(688331.SH)公布，本次回购的股份拟用于员工持股计划或股权激励，回购 股份金额不低于人民币2,000万元（含），不超过人民币4,000万元（含）。回购股份价格不超过95元/股 （含）。 ...

荣昌生物公告称，公司拟以集中竞价交易方式回购股份，金额不低于2000万元、不超4000万元，回购价 不超95元/股，数量为21.05万股至42.11万股，占总股本0.04% - 0.07%。资金源于自有或自筹资金，用于 员工持股计划或股权激励，若3年内未用完则注销。自董事会审议通过（2025年12月15日）起12个月内 实施。截至公告披露日，相关股东暂无未来3个月、6个月减持A股计划。回购存在价格、重大事项等风 险。 ...

荣昌生物公告，拟以2000万元-4000万元回购公司股份，回购价格不超过95元/股。 ...

Core Viewpoint - Rongchang Biopharma (09995) experienced a significant stock increase, with a rise of over 7% during trading, closing at 81.5 HKD, with a transaction volume of 310 million HKD, following the presentation of clinical trial data for its PD-1/VEGF bispecific antibody RC148 at the ESMO-IO conference in London [1] Group 1: Clinical Trial Data - The clinical study (RC148-C001) for RC148, a PD-1/VEGF bispecific antibody, was presented at the ESMO-IO conference, showing promising results for treating non-small cell lung cancer [1] - The study reported an overall response rate (ORR) of 66.7% and a disease control rate (DCR) of 95.2% for the RC148 20 mg/kg Q3W combined with docetaxel treatment [1] - Among PD-L1 positive patients (TPS≥1%), the ORR reached 80%, with a median follow-up time of approximately 7 months and a median progression-free survival (mPFS) of 8.3 months [1] Group 2: Regulatory Approvals and Market Potential - RC148 received FDA approval in August to initiate a Phase II clinical trial in the United States, marking its entry into global clinical development [1] - The drug has also been approved in China for clinical research in monotherapy and combination therapy for advanced solid tumors [1] - The increasing global business development (BD) activity in the PD-1/VEGF space, with companies like CanSino Biologics and 3SBio leading the way, indicates strong market potential for RC148 [1]

Group 1 - Rongchang Biologics (09995.HK) experienced a significant intraday increase of over 7%, with a current rise of 5.57%, trading at 81.5 HKD [2] - The trading volume reached 310 million HKD, indicating strong market interest [2]

Core Viewpoint - Rongchang Biologics (09995) experienced a significant stock increase, with a rise of over 7% during trading, closing at 81.5 HKD, with a transaction volume of 310 million HKD. This surge is attributed to the presentation of clinical trial data for their PD-1/VEGF bispecific antibody RC148 at the ESMO-IO conference in London, highlighting its promising efficacy in treating non-small cell lung cancer [1][1][1]. Group 1: Clinical Trial Data - The clinical trial data for RC148, presented at the ESMO-IO conference, showed a remarkable overall response rate (ORR) of 66.7% and a disease control rate (DCR) of 95.2% when combined with docetaxel at a dosage of 20 mg/kg every three weeks [1][1][1]. - Subgroup analysis revealed that patients with PD-L1 positive status (TPS≥1%) had an ORR of 80%, indicating significant efficacy across different patient groups [1][1][1]. - The median follow-up time for the trial was approximately 7 months, with a median progression-free survival (mPFS) of 8.3 months, further supporting the drug's potential effectiveness [1][1][1]. Group 2: Regulatory Approvals and Market Potential - RC148 received FDA approval to initiate Phase II clinical trials in the United States, marking a significant step in its global clinical development [1][1][1]. - Earlier in August, RC148 was also approved in China for clinical research in monotherapy and combination therapy for advanced solid tumors, showcasing its rapid progress in clinical development [1][1][1]. - The global business development (BD) activity surrounding PD-1/VEGF therapies is intensifying, with companies like Kangfang Biologics and 3SBio already pursuing international licensing agreements, indicating a competitive landscape and potential for RC148 to capitalize on this trend [1][1][1].

Core Viewpoint - Rongchang Biopharmaceutical (09995) experienced a significant stock increase, with a rise of over 7% during trading, closing at 81.5 HKD, with a transaction volume of 310 million HKD, following the presentation of clinical trial data for its PD-1/VEGF bispecific antibody RC148 at the ESMO-IO conference in London [1]. Group 1: Clinical Trial Data - The clinical trial data for RC148, a PD-1/VEGF bispecific antibody, was presented at the ESMO-IO conference, showcasing its efficacy in treating non-small cell lung cancer [1]. - The trial results indicated an overall response rate (ORR) of 66.7% and a disease control rate (DCR) of 95.2% for the 20 mg/kg Q3W dosage combined with docetaxel [1]. - Among patients with PD-L1 positive status (TPS≥1%), the ORR reached 80%, with a median follow-up time of approximately 7 months and a median progression-free survival (mPFS) of 8.3 months [1]. Group 2: Regulatory Approvals and Market Potential - RC148 received FDA approval in August to initiate a Phase II clinical trial in the United States, marking a significant step in its global clinical development [1]. - The drug has also been approved in China for clinical research in monotherapy and combination therapy for advanced solid tumors, indicating strong confidence in its clinical progress [1]. - The global business development (BD) activity for PD-1/VEGF therapies is heating up, with companies like Kangfang Biopharmaceutical and 3SBio already pursuing international licensing agreements, positioning RC148 favorably in the competitive landscape [1].

从资金流向上来看，当日生物制品板块主力资金净流出2.42亿元，游资资金净流入1.78亿元，散户资金净 流入6338.2万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 688331 | 荣昌生物 | -5217.72万 | 5.13% | 170.15万 | 0.17% | -5387.87万 | -5.30% | | 000534 万泽股份 | | 3663.99万 | 9.35% | -2332.45万 | -5.95% | -1331.55万 | -3.40% | | 688319 欧林生物 | | 2846.39万 | 12.93% | 395.57万 | 1.80% | -3241.96万 | -14.73% | | 688180 君实生物 | | 1294.25万 | 4.93% | 486.18万 | 1.85% | -1780.43万 | -6.79% | | 68 ...

据交易所数据显示，截至2025年12月8日收盘，荣昌生物（688331）报收于87.01元，下跌9.79%，换手 率7.11%，成交量11.55万手，成交金额10.16亿元。 资金流向方面，今日主力资金净流入5217.72万元，占比成交额5.13%。其中，超大单净流出385.23万 元、占成交额0.38%，大单净流入5602.96万元、占成交额5.51%，中单净流出流入170.15万元、占成交 额0.17%，小单净流出5387.87万元、占成交额5.3%。 荣昌生物最新一期业绩显示，截至2025三季报，公司营业总收入17.20亿元、同比增长42.27%，归属净 利润55070.06万元，同比增长48.60%，扣非净利润54524.42万元，同比增长50.31%，流动比率0.960、速 动比率0.728、资产负债率61.18%。 天眼查商业履历信息显示，荣昌生物制药(烟台)股份有限公司，成立于2008年，位于烟台市，是一家以 从事医药制造业为主的企业。企业注册资本56360.8243万人民币，实缴资本40181.9202万人民币。公司 法定代表人为王威东。 通过天眼查大数据分析，荣昌生物制药(烟台)股份有限公司 ...